Garg N, Padron EJ, Rammohan KW, Goodman CF. Bruton’s Tyrosine Kinase Inhibitors: The Next Frontier of B-Cell-Targeted Therapies for Cancer, Autoimmune Disorders, and Multiple Sclerosis. J Clin Med 2022; 11(20): 6139. [DOI: 10.3390/jcm11206139]
Gentry JJ, Barker PA, Carter BD. The p75 neurotrophin receptor: multiple interactors and numerous functions. Prog Brain Res 2004; 146:25-39. [DOI: 10.1016/S0079- 6123(03)46002-0]
Yanev S, Aloe L, Fiore M, Chaldakov GN. Neurotrophic and metabotrophic potential of nerve growth factor and brain-derived neurotrophic factor: linking cardiometa- bolic and neuropsychiatric diseases. World J Pharmacol 2013; 2(4): 92-99. [DOI: 10.5497/wjp.v2.i4.92]
Hirose M, Kuroda Y, Murata E. NGF/TrkA signaling as a therapeutic target for pain. Pain Practice 2016; 16(2): 175-182. [DOI: 10.1111/papr.12342]
Lee CK, Brown C, Gralla RJ, Hirsh V, Thongprasert S, Tsai C-M, et al. Impact of EGFR inhibitor in non–small cell lung cancer on progression-free and overall survival: a meta-analysis. J Nat Cancer Inst 2013; 105(9): 595-605. [DOI: 10.1093/jnci/djt072]
Gao G, Ren S, Li A, Xu J, Xu Q, Su C, et al. Epidermal growth factor receptor-tyrosine kinase inhibitor therapy is effective as first-line treatment of advanced non-small-cell lung cancer with mutated EGFR: a meta-analysis from six phase III randomized controlled trials. Int J Can- cer 2012; 131(5): E822-E829. [DOI: 10.1002/ijc.27396]
Okamura K, Harada T, Wang S, Ijichi K, Furuyama K, Koga T, et al. Expression of TrkB and BDNF is associated with poor prognosis in non-small cell lung cancer. Lung Cancer 2012; 78(1): 100-106. [DOI: 10.1016/j. lungcan.2012.07.011]
Sinkevicius KW, Kriegel C, Bellaria KJ, Lee J, Lau AN, Leeman KT, et al. Neurotrophin receptor TrkB promotes lung adenocarcinoma metastasis. Proc Natl Acad Sci USA 2014; 111(28): 10299-10304. [DOI: 10.1073/ pnas.140439911]
Collins C, Carducci MA, Eisenberger MA, Isaacs JT, Partin AW, Pili R, et al. Preclinical and clinical studies with the multikinase inhibitor CEP-701 as treatment for prostate cancer demonstrate the inadequacy of PSA response as a primary endpoint. Cancer Biol Ther 2007; 6(9): 1356-1363. [DOI: 10.4161/cbt.6.9.4541]
Festuccia C, Muzi P, Gravina GL, Millimaggi D, Speca S, Dolo V, et al. Tyrosine kinase inhibitor CEP-701 blocks the NTRK1/NGF receptor and limits the invasive capability of prostate cancer cells in vitro. Int J Oncol 2007; 30(1): 193-200. [DOI: 10.3892/ijo.30.1.193]
Shabbir M, Stuart R. Lestaurtinib, a multitargeted tyrosinse kinase inhibitor: from bench to bedside. Ex- pert Opin Invest Drugs 2010; 19(3): 427-436. [DOI: 10.1517/13543781003598862]
Lemmon MA, Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2010; 141(7): 1117-1134. [DOI: 10.1016/j.cell.2010.06.011]
Yang M, Sun J-Y, Ying C-C, Wang Y, Guo Y-L. Adipose-derived stem cells modified by BDNF gene rescue erectile dysfunction after cavernous nerve injury. Neural Regen Res 2020; 15(1): 120. [DOI: 10.4103/1673- 5374.264464]
Meldolesi J. Neurotrophin Trk receptors: new targets for cancer therapy. Rev Physiol Biochem Pharmacol 2018:174:67-79. [DOI: 10.1007/112_2017_6]
Meng L, Liu B, Ji R, Jiang X, Yan X, Xin Y. Targeting the BDNF/TrkB pathway for the treatment of tumors. Oncol Lett 2019; 17(2): 2031-2039. [DOI: 10.3892/ ol.2018.9854]
Liu C, Chan CB, Ye K. 7, 8-dihydroxyflavone, a small molecular TrkB agonist, is useful for treating various BDNF-implicated human disorders. Transl Neurodegen 2016; 5(1): 1-9. [DOI: 10.1186/s40035-015-0048-7]
Kopp F, Oak PS, Wagner E, Roidl A. miR-200c sensitizes breast cancer cells to doxorubicin treatment by decreasing TrkB and Bmi1 expression. PloS One 2012; 7(11): e50469. [DOI: 10.1371/journal.pone.0050469]
Long J, Jiang C, Liu B, Fang S, Kuang M. MicroRNA-15a-5p suppresses cancer proliferation and division in human hepatocellular carcinoma by targeting BDNF. Tumor Biol 2016; 37(5821-5828. [DOI: 10.1007/s13277- 015-4427-6]
Malekan M, Nezamabadi SS, Samami E, Mohebalizadeh M, Saghazadeh A, Rezaei N. BDNF and its signaling in cancer. J Cancer Res Clin Oncol 2022: 1-16. [DOI: 10.1007/s00432-022-04365-8]
Bronzetti E, Artico M, Forte F, Pagliarella G, Felici L, D‘Ambrosio A, et al. A possible role of BDNF in prostate cancer detection. Oncol Rep 2008; 19(4): 969-974. [DOI: 10.3892/or.19.4.969]
Dalal R, Djakiew D. Molecular characterization of neurotrophin expression and the corresponding tropomyosin receptor kinases (trks) in epithelial and stromal cells of the human prostate. Mol Cell Endocrinol 1997; 134(1): 15-22. [DOI: 10.1016/S0303-7207(97)00165-2]
Li W, Dou Z, We S, Zhu Z, Pan D, Jia Z, et al. Long noncoding RNA BDNF-AS is associated with clinical outcomes and has functional role in human prostate cancer. Biomed Pharmacother 2018; 102(1105-1110. [DOI: 10.1016/j.biopha.2018.03.118]
Wang L-w, Li J-l, Yu Y, Xiao R-h, Huang H-w, Kuang R-r, et al. Association of increased urine brain derived neurotrophic factor with lower urinary tract symptoms in men with benign prostatic hyperplasia. J Huazhong Univ Sci Technol [Med Sci] 2017; 37(4): 531-535. [DOI: 10.1007/s11596-017-1768-y]
Sornelli F, Fiore M, Chaldakov GN, Aloe L. Adipose tissue-derived nerve growth factor and brain-derived neurotrophic factor: results from experimental stress and diabetes. Gen Physiol Biophys 2009; 28(28): 179-183.
Tan J, Buache E, Chenard M-P, Dali-Youcef N, Rio M-C. Adipocyte is a non-trivial, dynamic partner of breast cancer cells. Int J Dev Biol 2011; 55(7-8-9): 851-859. [DOI: 10.1387/ijdb.113365jt]
Evtimov N, Hinev AI, Anakievski D, Zhelezov M, Ghenev PI, Chaldakov GN. Adipoparacrinology: periprostatic adipose tissue as an example. Adipobiology 2011; 3:61- 65. [DOI: 10.14748/adipo.v3.274]
Cao J-M, Chen LS, KenKnight BH, Ohara T, Lee M-H, Tsai J, et al. Nerve sprouting and sudden cardiac death. Cir Res 2000; 86(7): 816-821. [DOI: 10.1161/01. RES.86.7.816]
Ghenev PI, Kitanova MG, Popov HB, Evtimov N, Stoev SV, Tonchev AB, et al. Neuroadipobiology of arrhythmo- genic right ventricular dysplasia. An immunohistochemical study of neurotrophins. Adipobiology 2016; 8:55-58. [DOI: 10.14748/adipo.v8.2214]
Jeanneteau F, Chao MV. Promoting neurotrophic effects by GPCR ligands. In: Purinergic Signalling in Neuron–Glia Interactions. Novartis Foundation Symposium 276; 2006: Wiley Online Library; 2006. p. 181-192.
Lambiase A, Rama P, Bonini S, Caprioglio G, Aloe L. Topical treatment with nerve growth factor for corneal neurotrophic ulcers. New Engl J Med 1998; 338(17): 1174-1180. [DOI: 10.1056/NEJM199804233381702]
Aloe L, Tirassa P, Lambiase A. The topical application of
nerve growth factor as a pharmacological tool for human corneal and skin ulcers. Pharmacol Res 2008; 57(4): 253-258. [DOI: 10.1016/j.phrs.2008.01.010]
Yanev S, Fiore M, Hinev A, Ghenev P, Hristova M, Pan- ayotov P, et al. From antitubulins to trackins. Biomed Rev 2017; 27:59-68. [DOI: 10.14748/bmr.v27.2112]
Ostrovskaya RU, Gudasheva T, Zaplina A, Vahitova JV, Salimgareeva M, Jamidanov R, et al. Noopept stimulates the expression of NGF and BDNF in rat hippocampus. Bull Exp Biol Med 2008; 146:334-337. [DOI: 10.1007/ s10517-008-0297-x]
Levi-Montalcini R. The nerve growth factor 35 years later. Science 1987; 237(4819): 1154-1162. [DOI: 10.1126/ science.3306916]
Modoni S, Frangos S , Iakovou I , Michele Boero M, Mansi L. Theragnostics before we found its name. Q J Nucl Med Mol Imaging 2021;65(4):299-305. DOI: 10.23736/S1824-4785.21.03410-5
Abe T, Morgan DA, Gutterman DD. Protective role of nerve growth factor against postischemic dysfunction of sympathetic coronary innervation. Circulation 1997; 95(1): 213-220.
Bruno F, Arcuri D, Vozzo F, Malvaso A, Montesanto A, Maletta R. Expression and signaling pathways of Nerve Growth Factor (NGF) and pro-NGF in breast cancer: a systematic review. Curr Oncol 2022; 29(11): 8103-8120. [DOI: 10.3390/curroncol29110640]
Trouvilliez S, Cicero J, Leveque R, Aubert, L.; Corbet, C.; Van Outryve, A, et al. Direct interaction of TrkA/ CD44v3 is essential for NGF-promoted aggressiveness of breast cancer cells. J Exp Clin Cancer Res 2022; 41:110, doi:10.1186/s13046-022 02314-4
Tsang JY, Wong KH, Lai MW, Lacambra, MD, Ko CW, Chan SK, et al. Nerve growth factor receptor (NGFR): a potential marker for specific molecular subtypes of breast cancer. J Clin Pathol 2013;66:291-296. DOI:10.1136/ jclinpath2012-201027
Jung HH, Kim JY, Cho EY, Oh JM, Lee JE, et al. Elevated Level of Nerve Growth Factor (NGF) in Serum-Derived Exosomes Predicts Poor Survival in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy. Cancers (Basel) 2021;13:DOI: 10.3390/cancers13215260.
Chiarenza A, Lazarovici P, Lempereur L, Cantarella G, Bianchi A, Bernardini R. Tamoxifen inhibits nerve growth factor-induced proliferation of the human breast cancerous cell line MCF-7. Cancer Res 2001;61:3002-3008
Chaldakov GN, Fiore M, Tonchev AB, Aloe L. Adipopharmacology, a novel drug discovery approach: a metabotrophic perspective. Lett Drug Design Discov 2006; 3: 503–505.
Frohlich J, Chaldakov GN, Vinciguerra M. Cardio- and neurometabolic adipobiology: Consequences and implications for therapy. Int J Mol Sci 2021; 22(8): 4137. DOI:10.3390/ijms22084137
Chaldakov GN, Fiore M, Stankulov IS, Manni L, Hristova MG, Antonelli A, et al. Neurotrophin presence in human coronary atherosclerosis and metabolic syndrome: a role for NGF and BDNF in cardiovascular disease? Prog Brain Res 2004;146:279-89. DOI: 10.1016/S0079- 6123(03)46018-4
Manni L, Nikolova V, Vyagova D, Chaldakov GN, Aloe L. Reduced plasma levels of NGF and BDNF in patients with acute coronary syndromes.Int J Cardiol 2005;102:169-171. DOI: 10.1016/j.ijcard.2004.10.041
De la Monte SM, Wands JR, Alzheimer’s disease is type 3 diabetes – evidence reviewed. J Diabetes Sci Technol 2008; 2: 1101-1113.
Lee YH, et al. Amyloid precursor protein expression is upregulated in adipocytes in obesity. Obesity (Silver Spring) 2008;16:1493-500. DOI: 10.1038/ oby.2008.267.
Anagnostopoulou V, Pediaditakis I, Alkahtani S, Alarifi SA, Schmidt EM, Lang F, et al. Differential effects of dehydroepiandrosterone and testosterone in prostate and colon cancer cell apoptosis: the role of nerve growth factor (NGF) receptors. Endocrinology 2013;154:2446-2456. DOI: 10.1210/en.2012-2249.
Warrington RJ, Lewis KE. Natural antibodies against nerve growth factor inhibit in vitro prostate cancer cell metastasis. Cancer Immunol Immunother 2011; 60:187-195. DOI: 10.1007/s00262-010-0934-x.
Seth JH, Sahai A, Khan MS, van der Aa F, de Ridder D, Panicker JN, et al. Nerve growth factor (NGF): a potential urinary biomarker for overactive bladder syndrome (OAB)? Br J Urol 2013;111:372-380. DOI: 10.1111/j.1464-410X.2012.11672.x
Chakravarthy R, Mnich K, Gorman AM. Nerve growth factor (NGF)-mediated regulation of p75(NTR) expression contributes to chemotherapeutic resistance in triple negative breast cancer cells. Biochem Biophys Res Commun 2016; 478: 1541-1547. DOI: 10.1016/j. bbrc.2016.08.149
Aloe L, Rocco ML, Balzamino BO, Micera.A. Nerve growth factor: role in growth, differentiation and controlling cancer cell development. J Exp Clin Cancer Res 2016; 35:116. DOI: 10.1186/s13046-016-0395-y
Thiele CJ, Li Z, E. McKee AE. On Trk – the TrkB signal transduction pathway is an increasingly important target in cancer biology. Clin Cancer Res 2009; 15: 5962-5967. DOI: 10.1158/1078-0432.CCR-08-0651
De la Cruz-Morcillo MA, Berger J, Sánchez-Prieto R, Saada S, Naves T, Guillaudeau A, et al. p75 neurotrophin receptor and pro-BDNF promote cell survival and migration in clear cell renal cell carcinoma. Oncotarget 2016; DOI: 10.18632/oncotarget.8911
Kozisek ME, Middlemas D, Bylund DB. Brain-derived neurotrophic factor and its receptor tropomyosin-related kinase B in the mechanism of action of antidepressant therapies. Pharmacol Ther 2008; 117: 30-51.DOI: 10.1016/j.pharmthera.2007.07.001
Prior M, Dargusch R, Ehren JL, Chiruta C, Schubert D. The neurotrophic compound J147 reverses cognitive impairment in aged Alzheimer’s disease mice. Alzheimers Res Ther 2013; 5: 25. DOI: 10.1186/alzrt179
Povarnina PY, Vorontsova ON, Gudasheva TA, Ostrovskaya RU, Seredenin SB. Original nerve growth factor mimetic dipeptide GK-2 restores impaired cognitive functions in rat models of Alzheimer’s disease. Acta Naturae 2013; 5: 84-91. PMC:3848070
Artico M, Forte F, Pagliarella G, Felici LM, D’Ambrosio A, Vespasiani G, et al. A possible role of BDNF in prostate cancer detection. Oncol Rep 2008;194:969-74.
Chaldakov GN, Fiore M, Tonchev AB, Aloe L. Adipopharmacology, a novel drug discovery approach: a metabotrophic perspective. Lett Drug Design Discov 2006; 3: 503–505.
Weeraratna AT, Arnold JT, George DJ, DeMarzo A, Isaacs JT. Rational basis for Trk inhibition therapy for prostate cancer. Prostate 2000; 45:140-148.
Chiarenza A, Lazarovici P, Lempereur L, Cantarella G, Bianchi A, Bernardini R. Tamoxifen inhibits nerve growth factor-induced proliferation of the human breast cancerous cell line MCF-7. Cancer Res 2001; 61: 3002- 3008. PMID: 11306479